Core Insights - Predictive Oncology Inc. has entered into a standby equity purchase agreement (SEPA) with YA II PN, LTD, managed by Yorkville Advisors Global, LP, to secure funding for its drug discovery initiatives [1][2] - The SEPA allows Predictive Oncology to sell up to $10 million worth of its stock at its discretion, with no minimum commitments or penalties for non-use [2] - The company leverages its AI-driven platform, PEDAL, which predicts drug response with 92% accuracy, enhancing drug discovery for cancer treatment [4] Funding Agreement - The SEPA provides Predictive Oncology with a flexible funding source to support ongoing drug discovery, biomarker discovery, and drug repurposing efforts [1] - Yorkville is obligated to purchase the stock, but Predictive Oncology controls the timing and amount of sales [2] - There are no associated warrants, derivatives, or other share classes with the SEPA, and it does not restrict the company's operational activities [2] Company Overview - Predictive Oncology specializes in AI and machine learning applications in drug discovery, aiming to expedite the development of cancer treatments [4] - The company has a biobank of over 150,000 tumor samples, enhancing its drug discovery capabilities [4] - Predictive Oncology is headquartered in Pittsburgh, PA, and offers one of the industry's broadest AI-based drug discovery solutions [4]

PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB’s request for an expedited, two-day trial in July. The Court reached this decision citing RENB’s delay in bringing its action.  POAI fully intends to protect its rights and defend against the claims asserted by ...

Core Insights - Predictive Oncology Inc. is leveraging over 150,000 live cell tumor samples and drug response data to enhance drug discovery and biomarker identification using AI and machine learning [1][12] - Regeneron Pharmaceuticals' acquisition of 23andMe for $256 million signifies a strategic shift towards data-driven drug discovery, emphasizing the value of genomic databases in therapeutic development [2][5] - 23andMe's extensive genomic dataset provides insights into disease progression and treatment efficacy, making it a valuable asset for precision drug development [3][4] Company Developments - Predictive Oncology has achieved a milestone in AI-enabled cancer drug discovery by developing predictive tumor response models for 21 previously untested molecules targeting common cancer types [7][8] - The company's AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to a specific drug compound, facilitating informed drug selection for testing [11][12] - The integration of AI and machine learning with real-world drug response data allows Predictive Oncology to expedite early-stage drug discovery and reduce risks in drug development [9][10] Industry Trends - The acquisition of 23andMe by Regeneron reflects a broader trend in the biopharma industry towards the convergence of AI, real-world data, and predictive analytics to enhance therapeutic outcomes [5][10] - The life sciences sector is undergoing a transformation where the integration of genomics and machine learning is becoming a foundational element in precision medicine [10]

Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in 2024 and projected to grow at a 19.4% CAGR through 2030, Predictive Oncology is poised to lead in precision oncology innovation PITTSBURGH, May 20, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following shareholder update recapping recent p ...

Funds Raised in North Texas and Louisiana to Benefit the Work of LLS's The Dare to Dream Project to Bring Safer, Less Toxic Treatments for Kids with Blood Cancer & Provide Free Support & Resources for Their FamiliesDALLAS, May 14, 2025 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has partnered with Kroger's Dallas Division to raise funds in North Texas and Louisiana in support of The Dare to Dream Project. LLS is working to transform treatment and care for pediatric blood cancer patients and funds ...

New indications discovered by applying active machine learning and using samples from the company's vast biobank of live-cell tumors specimens "This efficient screening approach on a small, curated cohort of abandoned drugs identified three compounds that warrant further exploration in tumor indications that have never been examined in this way," said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology. "The work that we have done successfully de ...